🔗 Share this article

Given that America undertakes unprecedented changes to its vaccination schedules, an unexpected name has surfaced in a surprising turn: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by casting doubt on coronavirus vaccines during the global health crisis and has zeroed in on potential deaths following COVID-19 immunization in her recent tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Vaccine Schedule

Public health authorities planned to unveil radical revisions to the pediatric vaccination calendar earlier this month, bringing the US with the Danish immunization schedule, it is understood – a major change that would place the US out of step with much of the global community with little proof for public health gain. The announcement has been delayed until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to present at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth individual to run the division this year.

A Shift at the Agency

The acting appointment might represent a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a greater focus upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for halting some pediatric vaccine recommendations in the US to become more like the Danish model, a nation with nationalized medicine and a population about the population of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on immunizations – typically the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Background

Dr. Høeg has no obvious experience in medication creation, regulation or leadership, which has been typical for former heads of the biologics center. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since March.

“She appears not to have the necessary background” for overseeing the CDER, stated Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a large organization. She lacks background in pharmaceutical oversight.”

Former directors of CBER would “understand laws and regulations and the research of drug development”, commented Dr. Janet Woodcock. “Clearly, she lacks the type of experience that previous people who headed the center have had.”

CDER has an immense range of responsibilities at the FDA, she stated.

“Everybody just focuses on the innovative therapies, but the generic drug division approves thousands of generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and each of these must be looked after,” she said. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

There is also, a substantial management component to the role, which oversees more than 5,000 staff members. “It is a massive administrative position, if you do it right,” Woodcock concluded.

Official Statement and Contentious Policies

Regarding questions about Høeg’s credentials and whether this appointment signifies greater collaboration among agency officials on vaccines, a representative stated that the “inquiries stem from flawed assumptions”.

“This background is consistent with the responsibilities of her job,” the official explained, pointing to the time Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a contentious one-day drug-approval program that apparently troubled her predecessors. “By what process are these drugs being chosen for this fast-track system? Who is making the choices?” Dr. Howard asked. “There’s a lot of lack of transparency occurring at the FDA right now.”

In general, he stated, “the FDA seems to be moving towards less stringent rules of most medications, except for vaccines.”

Documented History on Vaccines

With immunizations, Dr. Høeg has a more documented, if problematic, past, critics said. She published a research paper using unverified volunteer-provided data to estimate the incidence of myocarditis following Covid immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are more dangerous than they are.

Among her “desired changes” for the current administration featured altering guidelines for new vaccines and discontinuing “unnecessary” immunizations, she said post-election on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of barring adolescent males from getting Covid vaccinations.

“She’s an complete ideologue who starts off with her beliefs and tailors the evidence to retrofit the science in a highly misleading, fraudulent manner,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow dissenters, {like|